| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Sonic Innovations, Inc. is a hearing aid company focused on the therapeutic aspects of hearing care. The Company designs, develops, manufactures and markets digital hearing aids. It has developed digital signal processing (DSP) technologies based on an
Sierra Nevada Children's Services is a Grass Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
US Re Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Houston, TX. To find more information about US Re Corporation, please visit www.usre.com
Health Care America Medical Group is a Bradenton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.